Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets

Trastuzumab in combination with chemotherapy has become a standard of care for patients with HER2+ breast cancer. The cost of therapy, however, can limit patient access to trastuzumab in areas with limited financial resources for treatment reimbursement. This study examined access to trastuzumab and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lammers, Philip, Criscitiello, Carmen, Curigliano, Giuseppe, Jacobs, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190498/
https://www.ncbi.nlm.nih.gov/pubmed/25232798
http://dx.doi.org/10.3390/ph7090943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190498/
https://www.ncbi.nlm.nih.gov/pubmed/25232798
http://dx.doi.org/10.3390/ph7090943

Ejemplares similares